Leerink Partners Raises Moderna Price Target but Maintains Underperform Rating

Key Facts

1Leerink Partners raised its price target for Moderna from $21 to $24.

2The firm maintained its 'Underperform' rating on the stock despite the price target adjustment.

Amid shifting dynamics in the post-pandemic biotech sector, Leerink Partners has adjusted its outlook on Moderna. According to reports, the firm raised its price target for the stock from $21 to $24. However, the analysts maintained an 'Underperform' rating, signaling continued caution as the company grapples with quarterly losses and broader market pressure on its core product lines.

This minor target adjustment occurs as Moderna faces stiff competition and sector-wide headwinds; for context, peer Pfizer has seen its shares decline by approximately 1.5% over the past month per market data. Analysts cited by Bloomberg indicate that the vaccine industry is struggling with a transition away from pandemic-era revenue levels, leading to a consensus of lowered earnings expectations across the mRNA technology space.

Traders should monitor the stock's performance relative to its current levels, with MRNA closing at $63.96 as of June 18, 2026. Looking ahead, upcoming US inflation data and manufacturing indices in the economic calendar will be key catalysts for growth-sensitive biotech stocks, as market participants weigh the impact of interest rate trajectories on research and development funding.